Clinical Trial Update: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating histamine H2 antagonists as add-on therapy for treatment-resistant schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Jesper Ekelund | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED